The combination therapy of HIF1 α inhibitor LW6 and cisplatin plays an effective role on anti-tumor function in A549 cells.

This study revealed that hypoxia-improved cisplatin chemoresistance of NSCLC cells by regulated MDR1 and MRP1 expression via HIF1α/ROS pathway is reversed by LW6, suggesting that LW6 may act as effective sensitizer in chemotherapy for NSCLC.
PMID: 31167534 [PubMed - in process]

Source: Neoplasma - June 2, 2019 Category: Cancer & Oncology Authors: Mai L, Luo M, Wu JJ, Yang JH, Hong LY Tags: Neoplasma Source Type: research